Home' Australian Pharmacist : Australian Pharmacist April 2014 Contents Australian Pharmacist April 2014 I ©Pharmaceutical Society of Australia Ltd.
Items in the Product news section are prepared from information provided by the companies named in each
item. They are included for the information of PSA members. It is up to the individual member to use their
professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses
nor confirms claims made in the items. (Where provided by the company references citing evidence are
included with the items.)
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest to all
pharmacists and which does not reflect unfavourably directly or by implication on the pharmacy profession or
the professional practice of pharmacy. Advertising which does not comply with this policy will be refused. It is
the responsibility of the advertisers to comply with the relevant Commonwealth and State law. Advertising does
not constitute an endorsement by PSA of the claims, products or services.
Read in greater detail more regularly than any other pharmacy title –
such constant behaviour means you can count on our readers to open
any issue and be seen!
» Greatest number of recipients opening and reading (82%)
» Greatest number of readers reading every issue (48%)
Engage with almost 18,800 PSA members every month (15,500
pharmacists in print and 16,000 in digital form).
» Australian Pharmacist is read by 65% of community pharmacists
It has an extremely strong CPD program followed by more than 10,000
pharmacists – a typical monthly article receives 3000 plus assessments,
with highs over 4000!
» Greatest average proportion read (73%)
» Circulation 14,872 cab March 2013
TO ADVERTISE in the best-read pages in pharmacy media and give your campaign real
impact, and greater recognition, contact Tremain Media.
Ph: 02 9988 4689
Ph: 02 9547 3001
Ph: 02 9871 5520
*Competitive Advantage Research August 2012 – 632 practicing community pharmacists
Australian‐owned Euky Bear Blitz Nitz is
a three‐step head lice control program
based on natural essential oils including
eucalyptus and tea tree. Blitz Nitz
Solution is clinically proven to kill lice
and eggs in five minutes according to
the company – the fastest product of its
kind on the market.
The Blitz Nitz launch, timed for the
beginning of the second school term in
April, is supported by extensive in‐store
POS and a media campaign including
prime‐time radio, PR, social media and
Euky Bear spokesperson Tegan Abbott
said Blitz Nitz unique super‐fast natural
formula was based on the company’s
many years of expertise in essential oils.
‘ We’ve been in essential oils for over
160 years with our Bosisto’s brand
and 35 years with Euky Bear and so
we knew we could make a natural
head lice product that was stronger,
faster and better value than what was
Blitz Nitz ‘three step’ total approach is
another key selling point. The range
includes Blitz Nitz Detective –
a conditioner that helps detect and
remove lice, Blitz Nitz Solution, which
kills 100% of lice in five minutes and Blitz
Nitz Detective, an everyday maintenance
shampoo with lice‐killing and repellent
properties. They come with a bonus
a lice removal comb or a re‐useable
The program also encourages education
about breaking the life cycle of lice,
using a free email alert system to remind
busy parents to treat the child’s hair at
three intervals – on Day 1, 7 and 14.
The Flutiform inhaler has been PBS listed
and is now available to asthma sufferers
in Australia. Using a new and effective
combination therapy, the Flutiform
inhaler brings together, for the first time,
the powerful ICS fluticasone propionate
with a fast‐acting LABA, eformoterol,
to provide asthma sufferers with rapid
onset of bronchodilation and sustained
improvements in lung function.
Coming as an aerosol delivered
by a metered dose inhaler with an
easy‐to‐read patient‐facing dose
counter, the simplicity of the Flutiform
inhaler combined with the rapid onset it
provides a new choice for sufferers that
may help them to achieve the goal of
improved long‐term management.
The majority of Australian’s with asthma
are relying on short‐term reliever therapy
to try and manage their condition, which
in itself is an indicator of poor control.
‘An optimal asthma treatment plan,’
says Associate Professor Greg King of the
Woolcock Institute of Medical Research,
‘should be simple to adhere to, eliminate
all symptoms of asthma and normalise
‘Pharmacists are well equipped to
advise people with asthma about
the importance of optimal asthma
management and what can be achieved
in getting it controlled. I would like to
see Pharmacists help people reach their
asthma management goals.
‘People with asthma need to be far less
accepting of the impacts of their asthma
and attain proper control so they can live
a full and satisfying life without putting
up with asthma symptoms’, A/Professor
Links Archive Australian Pharmacist March 2014 Australian Pharmacist May 2014 Navigation Previous Page Next Page